1,2-Piperazinedicarboxylic acid, 1,2-dimethyl ester | 280752-83-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1,2-Piperazinedicarboxylic acid, 1,2-dimethyl ester
• 英文别名: dimethyl piperazine-1,2-dicarboxylate
• CAS: 280752-83-2
• 化学式: C₈H₁₄N₂O₄
• 分子量: 202.21
• InChiKey: RRZHHWLLKANNQD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
  申请人：Abbott Laboratories

  公开号：US20040116518A1

  公开（公告）日：2004-06-17

  The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases and cerebral vasospasm, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

  本发明涉及新型肉桂酰胺化合物，用于治疗炎症和免疫性疾病以及脑血管痉挛，以及含有这些化合物的药物组合物，以及在哺乳动物中抑制炎症或抑制免疫反应的方法。
• [EN] COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DU CANCER ET ÉPIGÉNÉTIQUE
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2017061957A1

  公开（公告）日：2017-04-13

  Compounds For Inhibition Of Cancer and Epigenesis The present invention relates to quinolines and 5,6,7,8-tetrahydroacridines of the formula (I) wherein Z1, Z2, X, R1 to R8 and Y are defined as described in the specification, or a pharmaceutically acceptable form or prodrug thereof, that are inhibitors of methyl transferases such as protein lysine methyltransferases and more particularly SMYD3. The present invention also relates to the methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of disorders/conditions/diseases involving, relating to or associated with enzymes having methyl transferase activities/functions and/or via unspecified/multi-targeted mechanisms.

  抑制癌症和表观遗传学的化合物。本发明涉及式(I)的喹啉和5,6,7,8-四氢喹啉，其中Z1、Z2、X、R1至R8和Y的定义如说明书中所述，或其药学上可接受的形式或前药，它们是甲基转移酶的抑制剂，如蛋白赖氨酸甲基转移酶，特别是SMYD3。本发明还涉及它们的制备方法，含有这些化合物的药物组合物，以及这些化合物在治疗涉及、与或与具有甲基转移酶活性/功能的酶或通过未指定/多靶向机制相关的紊乱/疾病/疾病的用途。
• Cell adhesion-inhibiting anti-inflammatory and immune-suppressive compounds
  申请人：Abbott Laboratories

  公开号：EP1481968A2

  公开（公告）日：2004-12-01

  The present invention relates to cinnamide compounds of formula (I), in which at least one of R1 to R5 is a "cis-cinnamide" (a) or a "trans-cinnamide" (b) and the other variables are as defined in the claims, that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions containing these compounds and to methods of inhibiting inflammation or suppressing immune response in a mammal.

  本发明涉及式（I）的肉桂酰胺化合物，其中 R1 至 R5 中至少有一个是 "顺式肉桂酰胺"（a）或 "反式肉桂酰胺"（b），其他变量如权利要求中所定义，本发明涉及可用于治疗炎症和免疫疾病的肉桂酰胺化合物、含有这些化合物的药物组合物以及抑制哺乳动物炎症或抑制免疫反应的方法。
• CELL ADHESION-INHIBITING ANTIINFLAMMATORY AND IMMUNE-SUPPRESSIVE COMPOUNDS
  申请人：ABBOTT LABORATORIES

  公开号：EP1140814B1

  公开（公告）日：2005-05-25
• COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS
  申请人：Agency for Science, Technology and Research

  公开号：EP3371151A1

  公开（公告）日：2018-09-12